Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. 1982

B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll

The kinetic profiles of oral methimazole 40 mg, propranolol 80 mg, metoprolol 100 mg and atenolol 100 mg were compared in hyperthyroid patients both during the hyper- and euthyroid states. for methimazole, neither the peak concentration (Cmax), the time to reach peak concentration (tmax), the elimination half-life (t 1/2) nor the area under the curve (AUC) value was affected by the hyperthyroid state. For propranolol and metoprolol, which undergo extensive presystemic clearance, the AUC values were lower (p less than 0.02) when the patients were hyperthyroid than when they had become euthyroid, but the t 1/2's were not significantly altered. For atenolol, there were no significant kinetic differences between the hyperthyroid and euthyroid states. The findings are compatible with the assumption that hyperthyroidism does not affect the kinetics of methimazole or atenolol, but that it may enhance presystemic clearance of propranolol and metoprolol.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D005260 Female Females

Related Publications

B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
February 1983, Clinical endocrinology,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
January 1985, Arzneimittel-Forschung,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
January 1984, British journal of clinical pharmacology,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
January 1989, European journal of clinical pharmacology,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
January 2024, American journal of translational research,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
September 1981, Lancet (London, England),
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
September 1978, British journal of clinical pharmacology,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
April 1983, British journal of clinical pharmacology,
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
May 1983, British medical journal (Clinical research ed.),
B Hallengren, and O R Nilsson, and B E Karlberg, and A Melander, and L Tegler, and E Wåhlin-Boll
July 1990, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!